Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.

SALT LAKE CITY, Aug. 15, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth at the 16th Annual Next Generation Dx Summit, held virtually and in-person in Washington, D.C. on August 19-21, 2024.

Cambridge Healthtech Institute’s Next Generation Dx Summit is described as the nexus for international thought leaders to discuss diagnostic advancement and technology innovation, and offers a valuable window into how point-of-care, decentralized testing, infectious disease, liquid biopsy and companion diagnostics are changing the standard of care.

On Monday, August 19, at 12:15 PM ET, Company CEO Dwight Egan will be presenting on the Company’s forthcoming PCR platform, which is currently under FDA review and is not currently for sale, in a luncheon presentation titled “Co-Dx PCR Platform: The Future of Accessible Diagnostics.”

Attendees are invited to visit the Company at Booth #26 to learn more about the upcoming Co-Dx PCR testing platform as well as the Co-Dx Logix Smart® suite of clinical laboratory solutions. These solutions include Research Use Only (RUO) tests for mpox** virus, one of which was included in a study published in the Oxford Academic journal Open Forum Infectious Diseases in December, 2023. Yesterday, the World Health Organization Director-General declared mpox a public health emergency of international concern (PHEIC).

To learn more about the summit, including in-person and virtual registration details, please visit https://www.nextgenerationdx.com.

*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA and are not available for sale.

**The Co-Dx Logix Smart® Mpox and Co-Dx Logix Smart® Mpox 2-Gene tests are for Research Use Only. Not for use in diagnostic procedures.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-16th-next-generation-dx-summit-in-washington-dc-302223138.html

SOURCE Co-Diagnostics

Staff

Recent Posts

Laurel Bridge Software Advances Medical Imaging Workflow With New AI and Cloud Innovations at RSNA 2024

NEWARK, DE / ACCESSWIRE / November 22, 2024 / Laurel Bridge Software, a leader in…

55 minutes ago

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or…

55 minutes ago

Hemogenyx Pharmaceuticals PLC Announces Notice of Extraordinary General Meeting

Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Notice of Extraordinary General MeetingProposed Capital Reorganisation and New…

55 minutes ago

Sunshine Biopharma Launches a New Generic Prescription Drug

FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the…

55 minutes ago